CD274 and non-small cell lung carcinoma: While patients with the highest PD-L1 level of expression show the most benefit, a large proportion of NSCLC patients now receive immune checkpoint immunotherapy (ICI) at some point during their treatment, alone or in combination with chemotherapy, as recapitulated in this cohort.